Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012–2015)
Expert Opinion on Therapeutic Patents2016Vol. 26(7), pp. 815–832
Citations Over Time
Abstract
Although the clinical and preclinical data are reassuring, there is a lack of applicable drugs in daily clinical practice. However, the recent determination of enzyme structures considerably promoted the development of potent inhibitors, most of them having been designed as a structural analog of the natural enzyme substrate. Especially, the inhibition of indolamine 2,3-dioxygenase in central nervous system tumors, the inhibition of kynurenine aminotransferase in cognitive dysfunction, and the inhibition of kynurenine 3-monooxygenase in neurodegenerative disorders, such as Huntington's disease, each show great promise.
Related Papers
- → 4-Chloro-3-hydroxyanthranilate, 6-chlorotryptophan and norharmane attenuate quinolinic acid formation by interferon-γ-stimulated monocytes (THP-1 cells)(1993)98 cited
- → Frontal cortex indoleamine-2,3-dioxygenase activity is increased in HIV-1-associated dementia(1995)66 cited
- → Effect of indoleamine dioxygenase-1 deficiency and kynurenine pathway inhibition on murine cerebral malaria(2008)24 cited
- → Neuronal localization of indoleamine 2,3-dioxygenase in mice(2005)27 cited
- → IDO-1 mediated tryptophan catabolism – A MIE indicating formaldehyde induced immunotoxicity(2016)